42 completed, 34 recruiting, 27 unknown, 15 not yet recruiting. 48 Phase 2, 25 Not applicable, 18 Phase 3, 10 Phase 1, 5 Phase 4.
Follow Pathologic Complete Response: new trials by email Literature Review of Pathologic Complete Response trials Research Report on Pathologic Complete Response
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC) azacytidine, carboplatin, paclitaxel - Non-small Cell Lung Cancer (NSCLC), Carcinoma, Non-Small Cell Lung | Phase 1 / Phase 2 | Suspended | National Cancer Institute (NCI) | 60 | 2026-10-27 | 2026-10-22 |
| SHR-A1811 Versus Trastuzumab Plus Pertuzumab in ctDNA-Positive HER2-Positive Early Breast Cancer After Pathologic Complete Response SHR-A1811, Trastuzumab, Pertuzumab - HER2-positive Breast Cancer, Early Breast Cancer (EBC) | Phase 2 | Not yet recruiting | Fudan University | 358 | 2026-10-01 | 2026-10-02 |
| Surgery After Verifying Existing Disease in Locally Advanced Operable Lung Cancer: A Pilot Study Observation without surgery, Standard-of-care surgery - Non-Small Cell Lung Cancer, Immunotherapy | Phase 1 | Not yet recruiting | Centre hospitalier de l'Université de Montréal (CHUM) | 14 | 2026-10-01 | 2026-08-14 |
| Perioperative Adebrelimab for Locally Advanced Cervical Cancer Adebrelimab, Paclitaxel, Cisplatin - Locally Advanced Cervical Cancer | Phase 2 | Not yet recruiting | Anhui Provincial Hospital | 35 | 2026-10-01 | 2026-09-10 |
| Node-Sparing Short-Course Radiotherapy (25 Gy/5 Fractions) Combined With Chemoimmunotherapy as Neoadjuvant Treatment for Locally Advanced Esophageal Squamous Cell Carcinoma：A Prospective Single-Arm, Phase II Study Neoadjuvant SCRT + Camrelizumab + Nab-Paclitaxel/Carboplatin - ESCC | Phase 2 | Recruiting | Sixth Affiliated Hospital, Sun Yat-sen University | 33 | 2026-09-10 | 2026-09-09 |
| Supervised Exercise During Neoadjuvant Chemotherapy for Breast Cancer Supervised exercise - Breast Cancer Early Stage Breast Cancer (Stage 1-3), Breast Neoplasm Malignant Female | Not applicable | Not yet recruiting | King Hamad University Hospital, Bahrain | 80 | 2026-09-01 | 2026-08-13 |
| Penpulimab Combined With Chemotherapy for Patients With Locally Advanced Hypopharyngeal Carcinoma Finotonlimab, Nab-paclitaxel, carboplatin - Head & Neck Cancer | Phase 2 | Not yet recruiting | Tang-Du Hospital | 15 | 2026-08-23 | 2026-08-07 |
| Response-adapted Postoperative Radiotherapy In Locally Advanced Head and Neck Cancer Standard adjuvant radiotherapy based on pathologic findings, De-escalated radiotherapy with a reduced dose, De-escalated radiotherapy with omission of ENI - Head & Neck Squamous Cell Carcinoma, Locally Advanced Head and Neck Squamous Cell Carcinoma | Phase 2 | Not yet recruiting | Fudan University | 85 | 2026-08-01 | 2026-08-24 |
| Treatment Patterns and Survival Outcomes in High-Grade Osteosarcoma: A Multicenter Retrospective Study High-Grade Osteosarcoma | Recruiting | MedPacto, Inc. | 400 | 2026-07-13 | 2026-10-16 | |
| Oral Paclitaxel Solution With Immunotherapy and Concurrent SBRT as Neoadjuvant Treatment for Older Adults With NSCLC Oral Paclitaxel Solution, PD-1/PD-L1 inhibitor, Stereotactic Body Radiotherapy (SBRT) - NSCLC (Non-small Cell Lung Cancer) | Phase 4 | Recruiting | Shanghai Pulmonary Hospital, Shanghai, China | 78 | 2026-06-25 | 2026-08-10 |
| Intermittent Hypoxic Training as Neoadjuvant Therapy for Lung Squamous Cell Carcinoma Intermittent Hypoxic Training (IHT), Standard Neoadjuvant Chemo-immunotherapy - Lung Squamous Cell Carcinoma, Carcinoma, Non-Small-Cell Lung (NSCLC) | Phase 2 | Not yet recruiting | zhang yi | 60 | 2026-06-01 | 2026-06-01 |
| Circulating cfDNA and HPV as Prognostic Biomarkers for First-Line Recurrent Metastatic Cervical Cancer Biospecimen collection (peripheral blood and paraffin tumor tissue) - Cervical Cancer, Recurrent Cervical Cancer | Not yet recruiting | Zhejiang Cancer Hospital | 60 | 2026-06-01 | 2026-06-29 | |
| Perioperative Systemic Therapies in Muscle-Invasive Bladder Cancer (GUARDIANS) Perioperative Systemic Therapy Registry - Urothelial Carcinoma of the Bladder, Muscle Invasive Bladder Cancer (MIBC) | Recruiting | LMU Klinikum | 500 | 2026-05-17 | 2026-10-02 | |
| Vebectotamab Vedotin Combined With Pucotelimab in the Treatment of Locally Advanced Laryngeal Carcinoma Vibecotamab Injection - Head & Neck Cancer | Phase 1 / Phase 2 | Not yet recruiting | Tang-Du Hospital | 10 | 2026-04-23 | 2026-04-20 |
| Neoadjuvant FOLFOXIRI and Chemoradiotherapy Versus Neoadjuvant CAPOX/FOLFOX and Chemoradiotherapy Followed by Surgery or a Watch-and-Wait Approach in High Risk Locally Advanced Rectal Cancer FOLFOXIRI, CAPOX, FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin) - Locally Advanced Rectal Carcinoma | Phase 3 | Not yet recruiting | J. W. A. Burger | 394 | 2026-03-03 | 2026-03-16 |
| Short-Course Radiotherapy Combined With Chemotherapy and Immunotherapy in Mid-Low Locally Advanced Rectal Cancer Short-Course Radiotherapy Combined with Chemotherapy and Immunotherapy - Rectal Cancer, Adenocarcinoma, Rectal Cancer Stage II | Phase 2 | Not yet recruiting | Beijing Friendship Hospital | 19 | 2026-03-01 | 2026-02-11 |
| NECTAR Study: Neoadjuvant Toripalimab + 9MW2821 for Local UTUC Toripalimab, 9MW2821, Radical Nephroureterectomy with or without Lymph Node Dissection - Upper Tract Urothelial Carcinoma | Phase 2 | Not yet recruiting | Peking University Third Hospital | 40 | 2026-02-01 | 2026-02-17 |
| T Cell Lymphoma -Stratified Therapy After Response to First-line Treatment-CR Autologous Hematopoietic Stem Cell Transplantation, Observation - Peripheral T Cell Lymphoma | Recruiting | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 160 | 2026-01-20 | 2026-01-20 | |
| Romiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia After Complete Remission of Gastrointestinal Solid Tumors Romiplostim N01, All-trans retinoic acid - Persistent Isolated Chemotherapy-Induced Thrombocytopenia, Chemotherapy-Induced Thrombocytopenia | Phase 2 | Recruiting | Peking University People's Hospital | 220 | 2025-12-22 | 2026-05-14 |
| Romiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia After Complete Remission of Gynecologic, Breast, or Lung Solid Tumors Romiplostim N01, All-trans retinoic acid - Persistent Isolated Chemotherapy-Induced Thrombocytopenia, Chemotherapy-Induced Thrombocytopenia | Phase 2 | Recruiting | Peking University People's Hospital | 220 | 2025-12-22 | 2026-05-14 |
Showing 20 of 138. Sign in to see all of them.
Breast Neoplasms (32) · Rectal Neoplasms (18) · Leukemia, Myeloid, Acute (13) · Triple Negative Breast Neoplasms (8) · Carcinoma, Non-Small-Cell Lung (7) · Head and Neck Neoplasms (5) · Esophageal Squamous Cell Carcinoma (4) · Leukemia (4) · Neoplasm, Residual (4) · Motor Activity (3) · Multiple Myeloma (3) · Nasopharyngeal Carcinoma (3) · Neoplasm Metastasis (3) · Neoplasms (3)
Disease Attributes (138) · Disease Progression (138) · Pathologic Processes (138) · Pathological Conditions, Signs and Symptoms (137) · Neoplasms (102) · Neoplasms by Site (83) · Skin and Connective Tissue Diseases (38) · Neoplasms by Histologic Type (37) · Skin Diseases (37) · Breast Diseases (35) · Digestive System Diseases (27) · Gastrointestinal Diseases (27) · Digestive System Neoplasms (23) · Gastrointestinal Neoplasms (23) · Hemic and Lymphatic Diseases (22)
Carboplatin (11) · Trastuzumab (7) · Paclitaxel (6) · 130-nm albumin-bound paclitaxel (5) · Docetaxel (5) · Neoadjuvant Therapy (5) · Azacitidine (4) · Cisplatin (4) · Cyclophosphamide (4) · Cytarabine (4) · Fluorouracil (4) · Oxaliplatin (4) · pembrolizumab (4) · pertuzumab (4) · Capecitabine (3)
Sixth Affiliated Hospital, Sun Yat-sen University (6) · Henan Cancer Hospital (4) · Assistance Publique - Hôpitaux de Paris (3) · Tang-Du Hospital (3) · The Netherlands Cancer Institute (3) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (2) · Centre Leon Berard (2) · Fudan University (2) · M.D. Anderson Cancer Center (2) · Ming-Yuan Chen (2) · Peking University People's Hospital (2) · Sellas Life Sciences Group (2) · Shanghai Pulmonary Hospital, Shanghai, China (2) · Yale University (2) · Zhejiang Cancer Hospital (2)
China (47) · United States (28) · France (17) · Germany (11) · Netherlands (10) · Italy (9) · Belgium (7) · Brazil (7) · Australia (6) · Canada (6) · Poland (6) · Spain (6) · Russia (4) · South Korea (4) · Taiwan (4)
Zhenzhen Liu (4) · Xiangbo Wan, MD, PhD (3) · Michele Cavo, MD (2) · Ming-Yuan Chen, MD,PhD (2) · Xiaohui Zhang, MD (2) · Abbot R. Laptook, MD (1) · Abhik Das, PhD (1) · Alberto Zambelli, MD (1) · Amado Zurita, MD (1) · Amir Fathi, MD (1) · Andrea Botticelli, MD (1) · Andrew Kneebone, MBBS (1) · Angel Arnaout, MD (1) · Ann Van de Velde, MD, PhD (1)
PMID 18621575, PMID 19299237, PMID 19692142, PMID 20211870, PMID 20876174, PMID 21146205, PMID 21796368, PMID 22144537, PMID 22198468, PMID 22424952, PMID 22498745, PMID 22504098, PMID 22623692, PMID 22649152, PMID 23592699, PMID 23726546, PMID 23897961, PMID 24028546, PMID 24083350, PMID 24529560, PMID 25092775, PMID 25778529, PMID 27406346, PMID 27406347, PMID 27432930, PMID 27776843, PMID 27829371, PMID 27872127, PMID 28317872, PMID 28851423, PMID 28869790, PMID 29386195, PMID 29658848, PMID 30342494, PMID 30345884, PMID 30385039, PMID 30642373, PMID 30763338, PMID 30982686, PMID 31639132, PMID 31660903, PMID 32031889, PMID 32053137, PMID 32101663, PMID 32323313, PMID 32393788, PMID 32450725, PMID 32476546, PMID 32669709, PMID 32701140
2025 (2), 2005 (1), 2017 (1), 2018 (1), M01RR000030 (1), M01RR000032 (1), M01RR000039 (1), M01RR000044 (1), M01RR000054 (1), M01RR000059 (1), M01RR000070 (1), M01RR000080 (1), M01RR000633 (1), M01RR000750 (1), M01RR000997 (1)